LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

4.48 2.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.15

Max

4.55

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+40.23% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

60M

561M

Eelmine avamishind

2.2

Eelmine sulgemishind

4.48

Uudiste sentiment

By Acuity

17%

83%

19 / 352 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. veebr 2026, 22:04 UTC

Tulu

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26. veebr 2026, 23:55 UTC

Market Talk

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26. veebr 2026, 23:40 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26. veebr 2026, 23:37 UTC

Market Talk

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26. veebr 2026, 23:32 UTC

Tulu

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26. veebr 2026, 23:19 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26. veebr 2026, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26. veebr 2026, 23:12 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

26. veebr 2026, 23:12 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26. veebr 2026, 23:01 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 23:00 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26. veebr 2026, 22:55 UTC

Omandamised, ülevõtmised, äriostud

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26. veebr 2026, 22:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26. veebr 2026, 22:43 UTC

Market Talk

RBA Hike In March Is Being Underpriced -- Market Talk

26. veebr 2026, 22:33 UTC

Omandamised, ülevõtmised, äriostud

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26. veebr 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26. veebr 2026, 22:13 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26. veebr 2026, 21:59 UTC

Tulu

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26. veebr 2026, 21:58 UTC

Omandamised, ülevõtmised, äriostud

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26. veebr 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

26. veebr 2026, 21:49 UTC

Tulu

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26. veebr 2026, 21:45 UTC

Tulu

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26. veebr 2026, 21:44 UTC

Tulu

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26. veebr 2026, 21:44 UTC

Tulu

Coles Expects Market to Remain Highly Competitive

26. veebr 2026, 21:44 UTC

Tulu

Coles Says Supermarket Customers Remain Value Oriented

26. veebr 2026, 21:43 UTC

Tulu

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26. veebr 2026, 21:43 UTC

Tulu

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26. veebr 2026, 21:42 UTC

Omandamised, ülevõtmised, äriostud

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26. veebr 2026, 21:41 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

40.23% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD  40.23%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

1

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

19 / 352 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat